AKC Health Foundation – $2500
Clinical Trial for Evaluation of Propranolol and Doxorubicin in the Treatment of Canine Hemangiosarcoma
Hemangiosarcoma in dogs is an aggressive, malignant cancer of the blood vessels. Dogs are more affected by hemangiosarcoma than any other species of animal. Because it affects blood vessels, this type of cancer is often associated with sudden internal bleeding, which can be life-threatening for your dog. The severity of hemangiosarcoma depends on where it is found. This type of tumor can originate in several areas with the most common sites being the spleen, heart, skin, and liver. Only tumors found on the surface of the skin are considered to be curable and less serious than other areas. If the tumor is found early, complete surgical removal can cure your pet. If left to grow, cutaneous hemangiosarcoma can spread to other areas.
Treatment remains a challenge partly because the cancer is frequently detected at an advanced stage and because these tumors are often resistant to chemotherapies. Recently published reports showed that propranolol, a drug used to treat heart disease in humans and dogs, substantially increased the survival time of human angiosarcoma patients when used in combination with standard of care treatments. Propranolol was also shown to sensitize hemangiosarcoma cells to doxorubicin, providing a more effective way to kill tumor cells. Because angiosarcoma is strikingly similar to canine hemangiosarcoma, this multi-institutional clinical trial has been designed to determine the efficacy of propranolol in dogs with hemangiosarcoma when used in combination with surgery and chemotherapy. This trial will have a real benefit to humans as well.
The AKC Canine Health Foundation is supporting this multi-university clinical trial undertaken by a number of doctors from across the country including University of PA with a grant of $310,970 which runs from 7/1/2019 -6/30/2022.
AKC Canine Health Foundation – $2,500.00
01759: Disrupting the Differentiation of Cancer Stem Cells to Prevent the Spread of Hemangiosarcoma
Research Program Area: Oncology/Hemangiosarcoma
Principal Investigator: Dr. Jaime F Modiano, VMD PhD, University of Minnesota
$247,979.00, 1/1/2013 – 12/31/2015
AKC CANINE HEALTH FOUNDATION – $2,500.00
01787: Clinical Advancement of a Cancer Vaccine in Dogs
Dr. Nicola J Mason, BVetMed, PhD, University of Pennsylvania $96,660.00,
1/1/2013 – 12/31/2014
AKC CANINE HEALTH FOUNDATION – $2,500.00
01874-A: Identifying the Genes That Confer Risk for Development of Cataracts
Grant Amount: $12,960
Dr. Margaret R. Wallace,, University of Florida
September 1, 2012 – August 31, 2013
Disease(s): Cataracts
Research Program Area: Ophthalmology
AKC CANINE HEALTH FOUNDATION – $2,500.00
01874-A: Identifying the Genes That Confer Risk for Development of Cataracts
Grant Amount: $12,960
Dr. Margaret R. Wallace,, University of Florida
September 1, 2012 – August 31, 2013
Disease(s): Cataracts
Research Program Area: Ophthalmology
